Format

Send to

Choose Destination
Contraception. 2019 Jan 23. pii: S0010-7824(19)30014-9. doi: 10.1016/j.contraception.2019.01.001. [Epub ahead of print]

Rebound of medication abortion in Texas following updated mifepristone label.

Author information

1
Texas Policy Evaluation Project, Austin, TX; Ibis Reproductive Health, Oakland, CA. Electronic address: sbaum@ibisreproductivehealth.org.
2
Texas Policy Evaluation Project, Austin, TX; Department of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
3
Texas Policy Evaluation Project, Austin, TX; Population Research Center, University of Texas at Austin, Austin, TX.
4
Texas Policy Evaluation Project, Austin, TX; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Oakland, CA.

Abstract

BACKGROUND:

In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.

METHODS:

Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change.

RESULTS:

Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change.

CONCLUSIONS:

Use of medication abortion in Texas rebounded after the FDA label change.

KEYWORDS:

Abortion restrictions; House Bill 2; Medication abortion; Mifepristone; Texas

Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center